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Identifying genetic diagnoses for neurological conditions with a considerable hereditary 
component, such as autism spectrum disorder (ASD), intellectual disability, and epilepsy, is 
critical to providing proper medical management for these patients and their families. 
However, many patients with these conditions are not tested appropriately or receive no 
genetic testing at all (1).  The current study was designed to characterize the genetic testing 
practices of the providers most likely to evaluate or order genetic testing for these patients: 
pediatric neurologists, geneticists, and genetic counselors. The study noted significant variance 
between the testing strategies selected by pediatric neurologists compared to those of 
geneticists and genetic counselors and supports the need for updated guidelines that are 
consistent across specialties. Pediatric neurologists report lower confidence with ordering 
genetic testing and a need and desire for further education regarding genetic testing. This study 
proposes that the continued integration of genetic counselors into pediatric neurology clinics 
may improve utilization of genetic testing while reducing the burden on neurologists. 
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Introduction 
Many neurological conditions identified in childhood, such as autism spectrum disorder 
(ASD), epilepsy, and intellectual disability have a significant genetic component. Approximately 
1% of children living in the United States have ASD and 10% of those cases are due to an 
underlying genetic disorder, such as Fragile X syndrome (FXS) (2-5). Similarly, approximately 1% 
of the United States population has epilepsy and up to 3% of individuals with epilepsy have a 
genetic form (6, 7). Intellectual disability is found in approximately 1-3% of individuals, and, 
depending on the severity of the delay, 25-50% of those cases are related to a genetic 
abnormality(8). Given the significant chance of identifying a genetic etiology in many common 
childhood-onset neurological conditions, genetic testing offers considerable value to patients 
with these disorders, not only for diagnostic purposes, but also to determine if other specialty 
evaluations and treatments are indicated or if additional family members may have health or 
reproductive implications. For example, patients with ASD related to FXS should be screened 
for cardiac abnormalities and their family members may require evaluation for FXS or related 
health concerns. These recommendations differ greatly from those typically made for children 
with non-syndromic ASD (9).Therefore, children with ASD who do not receive testing for FXS 
may be missing necessary medical treatments and evaluations.  
Proper utilization of genetic testing involves not only patients receiving testing when 
indicated, but also the selection of the best testing strategy for a particular indication. 
Unfortunately, previous literature suggests many individuals with neurological conditions that 
warrant genetic testing do not receive recommended testing (1). Approximately 68% of 
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children with ASD do not receive any genetic testing despite current recommendations (1). For 
patients with ASD, the 2013 ACMG guidelines recommend chromosomal microarray (CMA) and 
FXS analysis. However, the most recent Child Neurology Society Guidelines for the screening 
and diagnosis of ASD recommends karyotyping and FXS analysis (10, 11). Notably, CMA was not 
used in clinical practice in 2000, the time of this publication. A similar pattern is seen for 
patients with unexplained intellectual disability. The American Academy of Pediatrics (AAP), 
American Academy of Neurology and American College of Medical Genetics and Genomics 
(ACMG) recommend CMA and FXS analysis as first-tier testing (12-14). By contrast, the relevant 
Child Neurology Society Guidelines from 2000, last updated in 2010, recommend karyotype 
analysis in addition to FXS analysis. Currently, there are no professional guidelines outlining 
proper genetic testing practices for patients with epilepsy. The variation in recommendations 
across specialties for these neurological conditions may present an obstacle to patients 
receiving recommended testing and appropriate medical care.  
In order to address the issue of proper utilization of genetic testing for patients with 
neurological conditions, it is necessary to gather data about the genetic testing practices of the 
practitioners that most commonly participate in ordering their genetic testing. The purpose of 
this study was to compare the attitudes and practices of pediatric neurologists, medical 
geneticists, and genetic counselors regarding genetic testing for pediatric patients with 
neurological conditions. Through doing so, this study aimed to identify where these providers 
differ in their utilization of genetic testing with the goal of informing plans to increase 
consistent and appropriate utilization of genetic testing for this patient population. 
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Methods 
Study Design 
 This was a cross-sectional study utilizing an electronic survey to assess the genetic 
testing practices of genetic counselors, geneticists, and pediatric neurologists. Approval of this 
study was granted by the Institutional Review Board at The University of Texas MD Anderson 
Cancer Center UTHealth Graduate School of Biomedical Sciences (IRB Number: HSC-GSBS-17-
0695).  
Genetic counselors, medical geneticists, and pediatric neurologists that are board-
certified in their field, see patients with neurological conditions at least once per month, and 
have ordered genetic testing within the last six months met the inclusion criteria for this study. 
Participants were contacted electronically, either personally or through the listserv of their 
respective professional organization. Genetic counselors were recruited from the National 
Society of Genetic Counselors via an initial electronic mail message and a follow up reminder 
three weeks later; while pediatric neurologists were contacted via the Child Neurology Society 
(CNS) listserv through a single electronic mail message. Medical geneticists were contacted by 
two personal electronic mail messages informing them of the option to participate in this study. 
Responses were collected over a period of approximately three months between September 
22, 2017 and December 10, 2017. 
Instrumentation 
The instrumentation used in this study was an investigator-designed, non-validated 
questionnaire hosted on Qualtrics®, an online survey software. All participants took the survey 
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online and their responses remained anonymous. Participants had the option to participate in a 
random drawing for one of two available gift cards by providing contact information that was 
not linked to the individual’s survey responses. 
The survey was divided into five sections: assessment of genetic testing utilization (11 
items), scoring of factors considered when deciding on a genetic testing strategy (4 items), 
assessment of testing practice for common indications (4 items), self-reported knowledge 
assessment of genetics topics (4 items), and demographic information (5 items). It was optional 
to answer each question. Question types included single choice, visual analog scale (VAS), and 
Likert scales (see appendix 1). The survey instrument was created specifically for this project 
and was reviewed for clarity and consistency by the authors. The instrument was not validated. 
Data Analysis 
 Data from Qualtrics was imported in STATA (v.13.0, College Station, TX) for analysis.  
Categorical variables are described using frequencies and percentages.  Continuous variables 
were not normally distributed and are described using medians and interquartile ranges (IQR).  
Comparison between clinician groups were made using contingency tests (chi-square or Fisher 
exact) for categorical variables and using Kruskal-Wallis test with a post-hoc Dunn’s test for 
continuous variables. Comparison of data between groups was evaluated using descriptive 
analysis.   Statistical significance was assumed at a Type I error rate of 5%.  
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Results 
Respondent Demographics  
Of the 397 individuals who opened the survey, 251 submitted a completed survey and 
met the inclusion criteria. Those responses included 103 genetic counselors, 35 geneticists, and 
113 pediatric neurologists (Figure 1).  
  
 
Figure 1:Responses flowchart describing inclusion and exclusion criteria  
 
Of the 251 respondents, 51% reported working in their field for 5 or fewer years, though 
this rate is highest among genetic counselors, at 79% (p<0.001). Genetic counselor respondents 
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were significantly more likely to be female (93%) than geneticist (61%) or pediatric neurologist 
respondents (48%) (p<0.001).  
 
  
Genetic Counselor 
n (%) 
Geneticist 
n (%) 
Neurologist 
n (%) 
Total 
n (%) 
Sex         
Male 7 (7) 12 (36) 52 (51) 71 (31) 
Female 87 (93) 20 (61) 49 (48) 156 (68) 
Other 0 (0) 1 (3) 1 (1) 2 (1) 
Age         
22-25 20 (22) 0 (0) 0 (0) 20 (9) 
26-30 42 (45) 0 (0) 2 (2) 44 (20) 
31-40 22 (24) 11 (34) 44 (44) 77 (34) 
41-50 4 (4) 10 (31) 28 (28) 42 (19) 
51-60 4 (4) 6 (19) 12 (12) 22 (10) 
>60 1 (1) 5 (16) 14 (14) 20 (9) 
 
Years Working in Specialty     
<1 13 (14) 1 (3) 2 (2) 16 (7) 
1-5 60 (65) 6 (19) 33 (33) 99 (44) 
6-10 10 (11) 8 (25) 25 (25) 43 (19) 
11-20 6 (6) 8 (25) 18 (18) 32 (14) 
21-30 3 (3) 5 (16) 11 (11) 19 (8) 
>30 1 (1) 4 (13) 12 (12) 17 (8) 
Active Patients at Practice       
<200 10 (11) 3 (9) 1 (1) 14 (6) 
201-500 15 (16) 4 (13) 18 (18) 37 (16) 
501-1000 14 (15) 5 (16) 17 (17) 36 (16) 
1001-3000 11 (12) 8 (25) 20 (20) 39 (17) 
>3000 10 (11) 7 (22) 28 (28) 45 (20) 
Not Sure 33 (35) 6 (19) 17 (17) 56 (25) 
Patient Insurance    
Predominantly Private 25 (27) 3 (10) 20 (21) 48 (22) 
Predominantly Medicaid 31 (34) 15 (48) 40 (42) 86 (39) 
Predominantly Military 2 (2) 0 (0) 2 (2) 4 (2) 
Mixed 34 (37) 13 (42) 33 (35) 80 (37) 
Table 1: Demographic information of respondents 
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Genetic Test Ordering Practices 
When asked about genetic testing practices, there was no difference in the number of 
genetic tests ordered in the past month between genetic counselors (median: 12, IQR: 5-20) 
and geneticists (median: 12, IQR: 8-25). However, neurologists reported a significantly lower 
number of tests ordered (median: 6, IQR: 4-10; p<0.001 for both). The respondents were also 
asked about the types of genetic testing that they have ordered in the last six months. 
Neurologists were found to be significantly less likely to order whole exome sequencing 
(p<0.001) compared to geneticists or genetic counselors. Genetic counselors are less likely to 
order or assist in ordering chromosome microarray than the other respondents (p=<0.001).  
Testing Strategies for Common Neurological Conditions 
Respondents selected the genetic test or tests they would order as first-tier testing for a 
patient with an isolated neurological condition (Table 2). Overall, genetic counselor and 
geneticist responses were not significantly different. However, many of the testing plans 
selected by the neurologists varied significantly from those chosen by the geneticists, genetic 
counselors, or both. 
Autism with Intellectual Disability: Respondents were most likely to select CMA and FXS 
analysis for the first line of testing they would offer to a patient with this indication (93% and 
84%, respectively). Only 2% of respondents overall selected that they would order no testing 
for this indication. Neurologists were significantly less likely to order Fragile X analysis than 
genetic counselors (p=0.041), less likely to order whole exome sequencing than genetic 
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counselors and geneticists (p=0.002), but more likely to order a karyotype for this indication 
(p=0.020). Most respondents (71%) included both tests currently recommended for first-tier 
testing, chromosome microarray and Fragile X analysis. Forty-eight percent of all respondents 
selected only these two tests. Of the respondents who selected CMA and Fragile X analysis for a 
patient with ASD and intellectual disability, 13.5% also reported that they would also order 
whole exome sequencing as a first line test for this patient. Within that same group, 22% 
reported they would order a karyotype in addition to a CMA and Fragile X analysis (12% of 
genetic counselors, 12 % of geneticists, and 27% of neurologists overall). 
Autism without Intellectual Disability (isolated ASD): CMA and Fragile X analysis were 
the most selected tests for this indication (73% and 51% respectively). Overall, 17% of 
respondents indicated that they are unsure of what testing to order, or their decision depends 
on additional information. Twenty-six percent of neurologists responded that they would not 
order any testing for isolated ASD, significantly more than genetic counselors or geneticists 
(p<0.001). Forty-nine percent of respondents included both chromosome microarray and 
Fragile X analysis when testing a patient with isolated ASD, and 33% selected those two tests 
exclusively. 
Intellectual Disability: CMA and Fragile X analysis were again the most selected tests for 
intellectual disability (88% and 60%, respectively). Sixteen percent of respondents reported that 
they did not know what testing they would choose, or that the decision would depend on 
additional information. In this case, neurologists were more likely to select that they would not 
order any testing (p=0.046), and less likely to choose CMA (p=0.001), Fragile X analysis 
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(p=0.007), or whole exome sequencing (p<0.001) for patients with intellectual disability. The 
respondents were most likely to select a combination of Fragile X and CMA when presented 
with a patient with isolated intellectual disability (29.1%). 
Epilepsy: The tests most likely to be selected to evaluate epilepsy were panel gene 
sequencing for related genes and CMA (63% and 41%, respectively). Approximately 28% of 
respondents reported that they were unsure of the testing they would order or would require 
more information. Neurologists were significantly more likely to report that they are 
unsure/require more information (p<0.001). Neurologists were less likely to order a CMA 
(p<0.001) or whole exome sequencing (p=0.002) than other respondents. For patients 
presenting with epilepsy, respondents were most likely to select panel testing alone (27.1%) or 
panel testing with CMA (13.6%) as their first-tier testing plan.  
Behavioral Problems: The respondents were most likely to select that they would not 
order any genetic testing for this condition (49%). The respondents who would order testing 
most commonly chose CMA (23%) or Fragile X analysis (13%). Neurologists were significantly 
more likely to select that they would order no testing (p<0.001) and less likely to choose CMA 
(p<0.001) or Fragile X analysis (p<0.001). 
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Genetic Counselor 
n (%) 
N = 94 
Geneticist 
n (%) 
N = 33 
Neurologist 
n (%) 
N = 103 
Total 
n (%) 
N = 230 
Autism with intellectual disability       
 
I would not order any testing 1 (1) 0 (0) 4 (4) 5 (2) 
Chromosome microarray 90 (96) 32 (97) 93 (90) 215 (93) 
Fragile X testing (FMR1 analysis) 85 (90) 29 (88) 80 (78) 194 (84) 
Whole exome sequencing 19 (20) 6 (18) 4 (4) †* 29 (13) 
Panel gene sequencing for related genes 11 (12) 2 (6) 9 (9) 22 (10) 
Single gene sequencing 1 (1) 1 (3) 0 (0) 2 (1) 
Karyotype/Chromosome analysis 12 (13) 4 (12) 28 (27) †* 44 (19) 
I don't know/it depends on other 
information 10 (11) 3 (9) 11 (11) 24 (10) 
Autism without intellectual disability    
 
I would not order any testing 6 (6) 1 (3) 27 (26) †* 34 (15) 
Chromosome microarray 78 (83) 30 (91) 59 (57) †* 167 (73) 
Fragile X testing (FMR1 analysis) 61 (65) 18 (55) 39 (38) †* 118 (51) 
Whole exome sequencing 9 (10) 1 (3) 2 (2) 12 (5) 
Panel gene sequencing for related genes 6 (6) 2 (6) 2 (2) 10 (4) 
Single gene sequencing 1 (1) 1 (3) 1 (1) 3 (1) 
Karyotype/Chromosome analysis 9 (10) 4 (12) 9 (9) 22 (10) 
I don't know/it depends on other 
information 19 (20) 3 (9) 18 (17) 40 (17) 
Epilepsy**    
 
I would not order any testing 2 (2) 0 (0) 6 (6) †* 8 (3) 
Chromosome microarray 52 (56) 18 (55) 24 (24) †* 94 (41) 
Fragile X testing (FMR1 analysis) 5 (5) 3 (9) 1 (1) 9 (4) 
Whole exome sequencing 16 (17) 8 (24) 4 (4) †* 28 (12) 
Panel gene sequencing for related genes 67 (72) 19 (58) 56 (55) 142 (62) 
Single gene sequencing 2 (2) 0 (0) 4 (4) 6 (3) 
Karyotype/Chromosome analysis 6 (6) 1 (3) 1 (1) 8 (3) 
I don't know/it depends on other 
information 18 (19) 3 (9) 42 (41) †* 63 (27) 
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Intellectual disability    
 
I would not order any testing 1 (1) 0 (0) 7 (0) †* 8 (3) 
Chromosome microarray 87 (93) 30 (91) 76 (73) †* 193 (84) 
Fragile X testing (FMR1 analysis) 67 (71) 21 (64) 51 (50) * 139 (60) 
Whole exome sequencing 16 (17) 9 (27) 2 (2) †* 27 (12) 
Panel gene sequencing for related genes 20 (21) 3 (9) 7 (7) * 30 (13) 
Single gene sequencing 1 (1) 0 (0) 0 (0) 1 (0) 
Karyotype/Chromosome analysis 10 (11) 3 (9) 16 (16) 29 (13) 
I don't know/it depends on other 
information 11 (12) 3 (9) 23 (22) 37 (16) 
Behavioral problems***    8 (3) 
I would not order any testing 37 (39) 8 (24) 66 (65) †* 111 (48) 
Chromosome microarray 30 (32) 14 (42) 8 (8) †* 52 (23) 
Fragile X testing (FMR1 analysis) 21 (22) 5 (15) 3 (3) †* 29 (13) 
Whole exome sequencing 1 (1) 0 (0) 0 (0) 1 (0) 
Panel gene sequencing for related genes 5 (5) 0 (0) 0 (0) * 5 (2) 
Single gene sequencing 0 (0) 0 (0) 0 (0) 0 (0) 
Karyotype/Chromosome analysis 3 (3) 1 (3) 3 (3) 7 (3) 
I don't know/it depends on other 
information 36 (38) 14 (42) 30 (30) 80 (35) 
* denotes a statistically significant difference compared to Genetic Counselor response (p ≤ 0.05) 
† denotes a statistically significant difference compared to Geneticist response (p ≤ 0.05) 
** Genetic counselor N = 93, Neurologist N = 102 
*** Neurologist N = 101 
 
 
Table 2: First-line genetic tests selected for isolated neurological conditions. 
 
Perceived Knowledge Assessment 
 Respondents rated their knowledge of topics related to neurogenetics (Table 3). 
Neurologists rated themselves significantly lower than geneticists for knowledge of molecular 
genetics (p<0.001) and testing guidelines for genetic neurological conditions (p=0.007), but 
ranked themselves highest for knowledge of genetic neurological conditions. 
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 When asked about their confidence on topics related to ordering genetic tests for 
patients, neurologists consistently reported the lowest levels of confidence. The statistical 
significance of these ratings (scaled from 1 to 5, with 5 being the highest level of confidence), 
are described below in Table 3. Neurologists reported significantly lower confidence on most 
topics: knowing when to order genetic tests, choosing the most appropriate test for a patient, 
interpreting test results, explaining test results to patients, and ordering tests to maximize 
diagnostic power while minimizing cost (p<0.001 for all). Neurologists were not significantly 
different from the other respondents with regard to their comfort handling the emotions that 
arise during a results disclosure. Notably, genetic counselors were less confident in knowing 
when to order genetic tests (p=0.001) and choosing the most appropriate test for a patient 
(p=0.013) compared to geneticists. 
A majority of neurologists responded yes when asked if they believed they would 
significantly benefit from further training on topics related to genetic testing, such as knowing 
when to order genetic tests, choosing the most appropriate test for a patient, interpreting test 
results, explaining test results, handling emotions during a results disclosure, and ordering tests 
to maximize diagnostic power and minimize costs (Table 3). A majority of genetic counselors 
and geneticists responded no to these same questions. 
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 Genetic Counselor 
N = 92 
Geneticist 
N = 33 
Neurologist 
N = 100     
Self-Reported Knowledge (VAS 1-10), mean (SD) 
   
Molecular Genetics 8.11 (1.62) 7.88 (1.80) 5.08 (2.43) †* 
Neurological Genetic Conditions 6.8 (1.63) 7.18 (1.42) 7.28 (1.82) * 
Testing Guidelines for Genetic Neurological 
Conditions 
6.71 (1.94)† 7.69 (1.71)* 6.51 (1.94) † 
    
Confidence in Ability (VAS 1-5), mean (SD) 
   
Knowing when to order genetic tests 4.23† (1.11) 4.67 (0.99) 4.17 (0.92) † 
Choosing the most appropriate test for a patient 4.13 (1.07)† 4.48 (1.00)* 3.75 (0.95)†* 
Interpreting test results 4.15 (1.06) 4.30 (0.92) 3.41 (1.08) †* 
Explaining test results to patients 4.49 (1.03) 4.45 (1.00) 3.79 (1.02) †* 
Handling emotions during result disclosure 4.22 (1.04) 4.24 (1.12) 3.94 (1.17) * 
Ordering tests to maximize diagnostic power and 
minimize cost 
4.26 (1.08) 4.22 (1.01) 3.24 (1.16) †* 
    
I would significantly benefit from more training 
on…, n (%) 
   
...When to order genetic testing 25 (27) 5 (15) 67 (71) †* 
...How to interpret test results 23 (25) 9 (27) 72 (75) †* 
...Counseling patients about genetic testing options 11 (12) 5 (15) 64 (67) †* 
...Explaining genetic testing results to patients 12 (13) 3 (9) 64 (67) †* 
        
* denotes a statistically significant difference compared to genetic counselor response (p ≤ 0.05)  
† denotes a statistically significant difference compared to geneticist response (p ≤ 0.05) 
Table 3: Self-rated knowledge and confidence regarding topics related to genetic testing for neurological conditions 
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Discussion 
Neurological conditions such as ASD, intellectual disability, and epilepsy have a 
significant hereditary component that warrants genetic testing. This study was conducted to 
characterize the genetic testing processes and practices of pediatric neurologists, geneticists, 
and genetic counselors. These results show a lack of consistency between the clinicians 
ordering genetic testing for pediatric neurological conditions and also identify areas where 
further education and refinement of guidelines relevant to genetic testing for these conditions 
would be valuable. 
 There is significant variance in the testing strategies selected by the responding 
members of these three professions. For the majority of questions requiring the participants to 
select a testing plan for an isolated condition, genetic counselors’ and geneticists’ responses 
were not significantly different from each other but were significantly different from the 
neurologists’ responses. Neurologists tended to be more likely to refrain from ordering testing, 
particularly for patients with isolated ASD or epilepsy. They are less likely to order Fragile X 
analysis for patients with ASD and/or intellectual disability and less likely to order chromosome 
microarrays or gene panels for patients with epilepsy. These differences in practice could mean 
that the genetic testing ordered for a patient is strongly influenced by whether their testing is 
ordered by a genetics specialist or a neurologist. In the case of autism, providers who are not 
ordering Fragile X for these patients are not providing a complete genetic evaluation, as 
outlined by current professional guidelines, including those published by the American College 
of Medical Genetics and Genomics (10). In addition, cases where providers are indicating that 
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they would order testing that is not listed as a recommendation by a professional organization’s 
guidelines may contribute to the over-ordering and improper use of genetic tests. 
 Current recommendations support ordering chromosome microarray and Fragile X 
analysis as first-tier tests for patients with ASD. Although a majority of respondents overall 
selected a testing plan in line with these recommendations, a significant number of 
respondents did not include one or both of those tests in their testing strategy. Currently, there 
are no professional guidelines for ordering genetic testing for patients with epilepsy published 
by the AAP, ACMG, or CNS. As a result, respondents were more likely to respond “I don’t 
know/it depends on other information” when asked about the testing they would order for a 
patient with epilepsy. This data shows that genetic testing guidelines, where they exist, are 
being followed inconsistently both within and across specialties. Some of the providers 
selecting testing plans that differ from published guidelines may be acting upon new research 
about genetic testing for neurological conditions released after the guidelines were published 
(15, 16). Others may be referring to outdated information, such as those ordering karyotypes 
rather than chromosome microarray for patients with ASD or intellectual disability. 
Additionally, the inconsistencies observed in the testing strategies of respondents point to a 
need for updated, collaborative guidelines that are accessible to and agreed upon by pediatric 
neurologists, geneticists, and genetic counselors.  
 This study identified pediatric neurologists as candidates for further education and 
training in ordering genetic testing, reflecting similar findings previously observed in 
neurologists (17). Though pediatric neurologists have responsibilities that extend far beyond 
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the scope of neurogenetics, the current trend towards increasing integration of genetics into 
other medical specialties suggests that ordering genetic testing and interpreting genetic testing 
results is a growing component of the medical management of patients being cared for by 
pediatric neurologists. The pediatric neurologists who participated in this study reported that 
they are receptive to and interested in further education about the proper clinical 
implementation of genetic testing and believe that genetic testing is currently underutilized in 
the field of neurology. For this reason, efforts to provide education about genetic testing to this 
population would likely be well-received. Inclusion of more genetic counselors in neurology 
clinics also may improve the utilization of genetic testing in these settings while limiting the 
amount of further training that neurologists require to feel comfortable ordering genetic 
testing for their patients. Genetic testing technology is rapidly evolving and many clinicians will 
not be aware of the latest advancements, particularly those whose primary specialty is not 
genetics. Genetic counselors in neurology clinics can stay apprised of guideline revisions and 
shift this responsibility away from neurologists. 
This study was limited in its statistical power by the comparatively few participating 
medical geneticists. Unlike genetic counselors and neurologists, geneticists were not reachable 
by listserv and were instead contacted personally. Additionally, the survey relied on self-
reported data, which may not be an accurate representation of the respondent’s actual genetic 
testing practices or knowledge of topics related to genetics. The survey tool used was not 
validated. As such, there is potential for respondents to interpret questions differently than 
intended. 
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 Future research should investigate methods for improving proper utilization of genetic 
testing for pediatric neurology patients, including examining the feasibility of incorporating 
more genetic counselors into pediatric neurology clinics and improving adherence to genetic 
testing guidelines. Research that investigates the testing practices of these providers with their 
actual patients via chart review would also add value to the field of pediatric neurology. 
In conclusion, this research shows inconsistencies in the testing ordered for common 
neurological conditions by neurologists, genetic counselors, and geneticists. Options exist to 
address this variation in practice, such as writing collaborative, updated guidelines addressing 
genetic testing for these conditions and incorporating genetic counselors and other genetics 
specialists into pediatric neurology clinics.  
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Appendix  
Section 1 (Inclusion/Exclusion) 
1. Which of the following best describes your job title?  
a. Neurologist 
b. Genetic Counselor 
c. Geneticist 
d. Other 
2. (If job selected is Neurologist) Do you primarily see patients under the age of 18? 
a. Yes 
b. No 
3. Do you see patients with neurological conditions (including developmental delay, 
autism, seizures, etc.) at least once every month?  
a. Yes 
b. No 
4. Are you board certified in your field? 
a. Yes 
b. No 
Section 2 
1. In the past 6 months, have you ordered/recommended genetic testing for a patient?  
a. Yes 
b. No 
c. I don’t know 
2. In the past month, approximately how many genetic tests for neurological conditions 
have you ordered/recommended be ordered for your patients?  
a. [Number entry] 
3. For what percent of the patients you see is a genetic test ordered? 
a. [Number entry – increments of 5] 
4. Of the tests that you have ordered for your patients in the last 6 months, approximately 
what percent of them were _____? Your answers should total 100. 
a. WES [Number entry] 
b. CMA [Number entry] 
c. Gene panel sequencing test (e.g. Epilepsy Panel)  [Number entry] 
d. Methylation analysis (e.g. Angelman/Prader-Willi Methylation Testing)  [Number 
entry] 
e. Triplet repeat expansion test (e.g. Fragile X Analysis) [Number entry] 
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f. Single gene sequencing test (e.g. SCN1A Sequencing) [Number entry] 
g. Other genetic test [Number entry] 
5. In the past 6 months, have you ordered/recommended a genetic test be ordered for the 
following conditions? 
a. Muscular dystrophy 
b. Neuropathy 
c. Spinal muscular atrophy 
d. Amyotrophic lateral sclerosis 
e. Ataxia 
f. Huntington Disease 
g. Dystonia 
h. Epilepsy 
i. Other neurological disorders 
6. (If job selected = neurologist or geneticist) Do you have access to a genetic counselor for 
referrals? 
a. Yes, we have one on our team 
b. Yes, I have access to an external genetic counselor 
c. No, I do not have access to a genetic counselor 
d. I am not sure 
7. In the past 6 months, approximately what percent of your new patients did you refer to 
genetic counseling? 
a. 0-10% 
b. 11-20% 
c. 21-30% 
d. 31-40% 
e. 41%-50% 
f. 51%-60% 
g. 61%-70% 
h. 71%-80% 
i. 81%-90% 
j. 91%-100% 
k. I do not refer patients to genetic counseling because a genetic counselor 
regularly sees each patient at my practice by default 
Section 3 
8. Below is a list of factors that you may consider when deciding on the genetic testing that 
you will offer a patient. Please rank each of the factors according to how often you 
consider those factors. [Likert scale: often an important factor, sometimes an important 
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factor, rarely an important factor, never an important factor. Also able to select “I am 
not sure how I weigh this factor”] 
a. Turnaround time 
b. Patient cost and/or insurance coverage 
c. Ability to interpret results 
d. Test validity 
e. Detection rate for suspected condition 
f. Likelihood of incidental findings 
g. Your confidence in a particular pre-testing clinical diagnosis 
h. Patient preference 
i. Ease of ordering 
9. Which of the following factors have you ever considered to be the most important 
consideration when deciding on the genetic testing you will offer a patient? [Select as 
many as apply] 
a. Turnaround time 
b. Patient cost and/or insurance coverage 
c. Ability to interpret results 
d. Test validity 
e. Detection rate for suspected condition 
f. Likelihood of incidental findings 
g. Your confidence in a particular pre-testing clinical diagnosis 
h. Patient preference 
i. Ease of ordering 
10. Matrix: What do you consider to be the most significant advantage of ordering a _____? 
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11. Matrix: What do you consider to be the most significant disadvantage of ordering a 
_____? 
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Intellectual Disability         
Behavioral Problems         
Epilepsy         
12. Why did you choose the testing strategy that you did for Autism with Intellectual 
Disability? (ex: follows professional recommendations, save cost to patient, likely to 
detect most common etiologies, took a guess, etc.) [Free response] 
13. Why did you choose the testing strategy that you did for Autism without Intellectual 
Disability? [Free response] 
14. Why did you choose the testing strategy that you did for seizures? [Free response] 
Section 5 
1. How would you rate your knowledge of…? (Likert Scale 1-10) 
a. Molecular genetics 
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b. Neurological genetic conditions 
c. Genetic testing guidelines for neurological conditions 
2. Do you believe you would significantly benefit from more training on? [Yes/No/Unsure} 
a. When to order genetic testing 
b. How to interpret results 
c. Counseling patients about genetic testing options 
d. Explaining genetic test results to patients 
3. The following question will assess your confidence about various elements of ordering 
genetic tests. [Likert Scale: Very unconfident, somewhat unconfident, neither confident 
nor unconfident, somewhat confident, very confident] 
a. Knowing when to order genetic tests 
b. Choosing the most appropriate test for a patient 
c. Interpreting test results, including variants of uncertain significance 
d. Explaining genetic test results to patients in a manner that is scientifically 
accurate and patient-friendly 
e. Handling the emotions that may arise during a genetic testing results disclosure 
f. Ordering tests in a manner that maximizes the diagnostic power of my testing 
plan while minimizing cost 
4. Do you believe that genetic testing is underutilized in the field of neurology in general? 
a. Strongly underutilized 
b. Somewhat underutilized 
c. Utilized the right amount 
d. Somewhat overutilized 
e. Strongly overutilized 
f. I’m not sure 
Section 6 (Demographics) 
1. What is your gender identity? 
a. Man 
b. Woman 
c. Other ______ 
2. What is your age? [Text Entry] 
3. How many years have you been working in your current specialty? Enter 0 if less than 1 
year. [Text Entry] 
4. In what state is your primary practice located? [Select state from dropdown menu] 
5. What is the number of active patients at your practice? 
a. Less than 200 
b. 201-500 
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c. 501-1000 
d. 1001-3000 
e. More than 3000 
f. I’m not sure 
6. Approximately what proportion of the patients you see are… [Number entry] 
a. Privately insured 
b. Insured by Medicaid 
c. Insured by the military (ex: Tricare) 
d. Uninsured/Self-pay 
Thank you for participating in this survey. If you wish to be entered for a chance to win one of 
two $50 Amazon gift cards, please follow the link and enter your email into the form. Your 
email will not be associated with your responses. [Link] 
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